![Eleven Things Labs Must Know to Comply with PAMA](https://www.g2intelligence.com/wp-content/uploads/2023/01/Feb23.LCA_.DV_.PAMA-iStock-1800x1250-1-1080x675.jpg)
Eleven Things Labs Must Know to Comply with PAMA
An overview of PAMA and key aspects lab compliance officers should be aware of to help ensure compliance.
An overview of PAMA and key aspects lab compliance officers should be aware of to help ensure compliance.
Recent OIG report suggests some labs might have gamed Medicare coverage rules in 2020 by billing for unusually high numbers of such tests.
Researchers report the first-ever routine clinical use of an AI-based tool for breast cancer biopsies in a pathology lab.
Experts share new strategies for dealing with hemolysis, icterus, and lipemia interference.
In a new practice guideline, the group also “strongly recommends” that NIPS be offered to patients to screen for fetal SCA.
More companies have begun offering neurofilament light chain blood tests as a cost-effective alternative to conventional methods.
The test manufacturer is the first to gain IVDR certification for a companion diagnostic under the new regulation.
A recent CDC report concludes that disruptions to HIV testing due to the COVID-19 pandemic compromised America’s ability to prevent the disease.
While labs were absent from recent enforcement actions, last week saw kickback schemes involving DME companies and a medical device company.
Some labs took advantage of COVID coverage rules to bill Medicare for medically unnecessary RPPs, allergy, and genetic tests.